Cargando…
Microencapsulated phages show prolonged stability in gastrointestinal environments and high therapeutic efficiency to treat Escherichia coli O157:H7 infection
Escherichia coli (E. coli) O157:H7 bacterial infection causes severe disease in mammals and results in substantial economic losses worldwide. Due to the development of antibiotic resistance, bacteriophage (phage) therapy has become an alternative to control O157:H7 infection. However, the therapeuti...
Autores principales: | Yin, Hanjie, Li, Jing, Huang, Haosheng, Wang, Yuxin, Qian, Xinjie, Ren, Jianluan, Xue, Feng, Dai, Jianjun, Tang, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439058/ https://www.ncbi.nlm.nih.gov/pubmed/34521472 http://dx.doi.org/10.1186/s13567-021-00991-1 |
Ejemplares similares
-
Oral phage therapy with microencapsulated phage A221 against Escherichia coli infections in weaned piglets
por: Mao, Xinyu, et al.
Publicado: (2023) -
Phage Cocktail Targeting STEC O157:H7 Has Comparable Efficacy and Superior Recovery Compared with Enrofloxacin in an Enteric Murine Model
por: Wang, Yuxin, et al.
Publicado: (2022) -
Microencapsulated phage composites with increased gastrointestinal stability for the oral treatment of Salmonella colonization in chicken
por: Zhang, Bo, et al.
Publicado: (2023) -
Analysis of whole genome sequencing for the Escherichia coli O157:H7 typing phages
por: Cowley, Lauren A, et al.
Publicado: (2015) -
Characterization of a ViI-like Phage Specific to Escherichia coli O157:H7
por: Kutter, Elizabeth M, et al.
Publicado: (2011)